Selection of antibiotic-resistant bacteria: Microbiological and pharmacological factors

Medicina Clinica

Volumn 117, Issue 16, 2001, Pages 632-636

  Soriano, S ^a  

^a Fundac Jimémenez Diaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; METRONIDAZOLE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIUM IDENTIFICATION; BACTEROIDES; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; MICROBIOLOGY; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; BACTERIAL GENE; GENETICS; MICROBIOLOGICAL EXAMINATION; MUTATION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 0035904802     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(01)72202-6     Document Type: Review

References (50)

1. Minimizing quinolone resistance: Are the new agents more or less likely to cause resistance?
2. The prevention of antibiotic resistance during treatment
3. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus
4. Antimicrobial action and pharmacokinetics/pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance
5. Pharmacodynamic modeling of bacterial kinetics: β-lactam antibiotics against Escherichia coli
6. Frequency of appearance of resistant variants to norfloxacin and nalidixic acid
7. In vitro development of resistance to ceftriaxone, cefprozil and azithromycin in Streptococcus pneumoniae
8. Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus
9. Dissociated resistance among fluoroquinolones
10. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: Novel pleiotropic effects on quinolone and coumarin activity
11. Optimal dosage of β-lactam antibiotics: Time above the MIC and inoculum effect
12. Correlation of pharmacodynamic parameters of five β-lactam antibiotics with therapeutic efficacy in an animal model
13. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis
14. A strategy for fighting antibiotic resistance
15. Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureus
16. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
17. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
18. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics
19. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
20. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: Effect of simultaneous versus staggered administration in an in vitro model of infection
21. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
22. Antimicrobial resistance issues of the future
23. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models
24. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
25. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
26. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication
27. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
28. Levofloxacin pharmacodynamics vs. Streptococcus pneumoniae
29. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
30. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
31. Pharmacodynamics to combat resistance
32. Evaluation of the activity of the newer fluorquinolones against ciprofloxacin- resistant Streptococcus pneumoniae
33. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model
34. Pharmacodynamic outcome parameters as predictors for fluoroquinolones in the treatment of anaerobic infections
35. Effect of schedule of administration on the therapeutic efficacy of penicillin
36. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad- spectrum cephalosporins
37. Treatment of experimental endocarditis due to penicillin- resistant Streptococcus pneumoniae
38. Relevance of the Alexander Project: Pharmacodynamic considerations
39. Role of Streptococcus pneumoniae and Haemophilus influenzae in the development of acute otitis media and otitis media with effusion in a gerbil model
40. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
41. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
42. Kinetics of antibiotics in relation to effective and convenient outpatient parenteral therapy
43. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis
44. Eradication of bacterial pathogens from middle ear infections
45. Microbiologic efficacy of antibacterial drugs for acute otitis media
46. Penicillin- resistant Streptococcus pneumoniae in acute otitis media: Risk factors, susceptibility patterns and antimicrobial management
47. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin
48. Evaluation of nasopharyngeal cultures for bacteriological assessment of acute otitis media in children
49. Impact of antimicrobial therapy on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Branhamella catarrhalis in children with respiratory tract infections
50. Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media